Abstract:Background: Protein N-myristoylation is the linkage of the fatty acid myristate to the N-terminus of a protein. Catalyzed by two human enzymes – N-myristoyltransferase 1 & 2 (NMT1/2) – this modification alters the stability, localization, complex association, and function of proteins. Up to 600 myristoylated human proteoforms impact a wide variety of processes including signal transduction, cytoskeletal rearrangement, apoptosis and metabolism. We reported the importance of myristoylation of Src-family kinases (SFKs) for B-cell receptor signaling in B-cell lymphomas; treating cells with first-in-class myristoylation inhibitor PCLX-001 rapidly led to cell death. In acute myeloid leukemia (AML), two frequently mutated receptor tyrosine kinases, FLT3 and c-Kit, rely upon SFKs for signal transduction, leading us to explore the therapeutic potential of PCLX-001 in AML. A challenge in treating AML is leukemic stem cells (LSCs); a rare, self-renewing population which frequently survives therapy, expanding to re-establish disease. The heterogeneity of LSCs adds further complexity as therapies result in the enrichment of drug-resistant clones leading to refractory disease. New AML therapies thus require targeting LSCs. Recent reports showed that LSCs have a relatively inflexible metabolism, rely on oxidative phosphorylation (OXPHOS) for survival and that inhibition of OXPHOS led to LSCs killing. Aims: To demonstrate the efficacy of myristoylation inhibitor PCLX-001 in AML, elucidate its mechanism of action, and evaluate its ability to target LSCs. Methods: Efficacy of PCLX-001 against AML cell lines in comparison to PBMCs and lymphocytes from healthy individuals was determined by CellTiterBlue viability assay. SFK proteins, SFK activation, ER stress, and apoptosis induction were examined by western blotting. PCLX-001 efficacy against LSCs was examined using OCI-AML-22 cell model by assaying viability of LSC-enriched fractions. In vivo efficacy was determined using tail vein and intra-femoral murine xenografts of primary patient samples; mice were treated with PCLX-001 and blood or marrow collected for flow cytometric analysis for engrafted cells. Seahorse and Resipher platforms were used to measure oxygen consumption rates (OCR) in AML cell lines. Levels of myristoylated mitochondrial complex I proteins NDUFAF4 and NDUFB7 were measured by western blotting. Levels of total complex I and its in-gel activity were measured after blue native gel electrophoresis of isolated mitochondria. Results: PCLX-001 treatment induced cell death in AML cell lines at concentrations that spared healthy PBMCs and lymphocytes. PCLX-001 treatment resulted in loss of total SFKs and SFK phosphorylation leading to an increase in ER stress (Bip protein) and apoptosis (caspase 3 cleavage). In OCI-AML-22, LSC-enriched population viability was reduced in response to PCLX-001 treatment after 48 hours, and bulk populations after 72 hours. In vivo, PCLX-001 treatment reduced the numbers of AML cells circulating in the blood and marrow. PCLX-001 produced a dose-dependent reduction in OCR in treated AML cells, and a corresponding loss of NDUFAF4 and NDUFB7 proteins, and complex I assembly and activity. Summary/Conclusion: We demonstrate PCLX-001 kills bulk leukemic cells and LSCs in vitro and in vivo by disrupting the function of key myristoylated proteins. While PCLX-001 is currently undergoing clinical evaluation in B-cell lymphoma and solid tumours, these results warrant clinical evaluation in AML with trials scheduled to start spring 2023. Keywords: Acute myeloid leukemia, Cancer, Src kinase, Mitochondria

Small molecule targeting of FBXO21 mediated p85αubiquitylation in acute myeloid leukemia

Targeting a lineage-specific PI3Kɣ-Akt signaling module in acute myeloid leukemia using a heterobifunctional degrader molecule

A Pyridinesulfonamide Derivative FD268 Suppresses Cell Proliferation and Induces Apoptosis Via Inhibiting PI3K Pathway in Acute Myeloid Leukemia

Targeting Molecular Signaling Pathways and Cytokine Responses to Modulate c-MYC in Acute Myeloid Leukemia

Targeting PI3K, Mtor, ERK, and Bcl-2 Signaling Network Shows Superior Antileukemic Activity Against AML

In silico predicted compound targeting the IQGAP1-GRD domain selectively inhibits growth of human acute myeloid leukemia

Small-molecule inhibitor of AF9/ENL-DOT1L/AF4/AFF4 interactions suppresses malignant gene expression and tumor growth

Discovery of N-(2-chloro-5-(3-(pyridin-4-yl)-1H-pyrazolo[3,4-b] Pyridin-5-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide (FD274) As a Highly Potent PI3K/mTOR Dual Inhibitor for the Treatment of Acute Myeloid Leukemia

P465: N-MYRISTOYLATION INHIBITION ABROGATES OXIDATIVE PHOSPHORYLATION TO TARGET ACUTE MYELOID LEUKEMIA STEM CELLS

Rational design and optimization of novel 4-methyl quinazoline derivatives as PI3K/HDAC dual inhibitors with benzamide as zinc binding moiety for the treatment of acute myeloid leukemia

Discovery of highly potent p53-MDM2 antagonists and structural basis for anti-acute myeloid leukemia activities.

Novel PIKfyve/Tubulin Dual-target Inhibitor As a Promising Therapeutic Strategy for B-cell Acute Lymphoblastic Leukemia.

A novel iheyamine A derivative L42 suppresses acute myeloid leukemia via dual regulation of the PI3K/AKT/FOXO3a axis and TNF signaling pathway

3023 – ELUCIDATING THE MECHANISMS OF LEUKEMOGENESIS DRIVEN BY FBXO11 LOSS

Abstract 525: Targeting interleukin-1 receptor-associated kinase 1/4 in acute myeloid leukemia stem cells

Discovery of novel and potent CDK8 inhibitors for the treatment of acute myeloid leukaemia

A small molecule BCL6 inhibitor as chemosensitizers in acute myeloid leukemia

The Ubiquitin-Activating Enzyme E1 As a Therapeutic Target for the Treatment of Leukemia and Multiple Myeloma.

Pharmacologic Inhibition of MNKs in Acute Myeloid Leukemia

Abstract 2030: Inhibition of IRE1α-XBP1 pathway is a promising therapeutic application in acute myeloid leukemia.

Design and Optimization of Selective and Potent CDK9 Inhibitors with Flavonoid Scaffold for the Treatment of Acute Myeloid Leukemia.